Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …

Gliflozins are a novel class of oral anti-diabetic drugs, acting as inhibitors of sodium-glucose
co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

Alzheimer's disease (AD) is the sixth leading cause of death in the USA today; therefore, it is
imperative that public health initiatives and clinical strategies are developed to prevent and …

Abstract Alzheimer's disease (AD), the most frequent cause of dementia, is escalating as a
global epidemic, and so far, there is neither cure nor treatment to alter its progression. The …

Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and
dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 …

Abstract Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share
common pathological features including inflammation, insulin signaling alterations, or …

Objective Diabetes is a risk factor for dementia, but whether antidiabetic medication
decreases the risk is unclear. We examined the association between antidiabetic medication …

The number of diabetic patients has risen dramatically in recent decades, owing mostly to
the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic …

Background Preclinical studies have suggested potential beneficial effects of newer glucose‐
lowering drugs (GLDs) including dipeptidyl peptidase (DPP)‐4 inhibitors, glucagon‐like …